U.S. stock night market volatility: Night market up 4.10%, clear capital flow, increased volatility attracts market attention!

U.S. Stock Night Market Movements BGM, up 4.10% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Eli Lilly is up 2.02% in the night market. Based on recent key news: On February 4, Eli Lilly announced its fourth-quarter results, with revenue of $19.29 billion, a year-on-year increase of 43%, and adjusted earnings per share of $7.54, exceeding market expectations, leading to an 8% pre-market price increase. Source: Zhitong Finance On February 4, Eli Lilly raised its revenue guidance for 2026 to $80-83 billion, surpassing market expectations, driving the stock price up. Source: Wall Street Insight On February 5, JP Morgan raised Eli Lilly's target price from $115 to $130, reflecting analysts' confidence in the company's future growth. Source: Jinshi Data. The pharmaceutical industry shows strong demand, with evident capital inflows. Novo Nordisk is up 2.58% in the night market. Based on recent news: On February 4, Novo Nordisk announced its sales and operating profit outlook for 2026, expecting adjusted sales to decline by 5% to 13%, raising market concerns. On February 4, Novo Nordisk reported earnings per share of 1.02 Danish Krone, higher than the market expectation of 0.92 Danish Krone, boosting the stock price. On February 4, the CEO of Novo Nordisk stated that the company is facing unprecedented pricing pressure, increasing market uncertainty. The industry is under pricing pressure, and future trends need to be monitored. Johnson & Johnson is up 1.16% in the night market. Based on recent key news: On February 3, Johnson & Johnson announced its participation in the TD Cowen Annual Healthcare Conference, which may attract investor attention. The company's management will hold a fireside chat at the conference, expected to discuss future strategies, driving the stock price up. On February 5, Citigroup analysts reinstated a buy rating on Johnson & Johnson stock, with a target price of $185. Analysts are optimistic about Johnson & Johnson spinning off its consumer health business into an independent publicly traded company, boosting market confidence, leading to a stock price increase. On February 5, market analysis showed that Johnson & Johnson was not included in the list of top five stocks recommended by leading analysts; nevertheless, Johnson & Johnson still maintains a moderate buy rating, indicating a cautiously optimistic market outlook for its future performance. The pharmaceutical industry has shown strong recent performance, with evident capital inflows